Completion of Business Combination between Kinarus Therapeutics and Curatis AG

Curatis Holding AG, formerly known as Kinarus Therapeutics Holding AG, has announced the successful completion of its business combination with Curatis AG. The transaction concluded on April 25, 2024, leading to the first trading day of Curatis Group under the ticker symbol CURN.SW on April 26, 2024. This merger introduces a newly structured entity on the SIX Swiss Exchange, serving the specialty pharmaceutical sector with a focus on orphan and ultra-orphan diseases.

During this reorganization, a total of CHF4.36 million was secured in the first quarter of 2024. Curatis Group carried out a reverse share split and a small capital increase, simplifying its share structure. The major aspect of this business combination included acquiring all outstanding shares of Curatis AG, with a total consideration involving the issuance of 4,093,916 newly issued CURN.SW shares.

Curatis Group’s business model integrates the distribution of specialty medicines with drug development focused on safety and efficacy for high unmet medical needs. With the merger, Curatis aims to expand its distribution network across major European markets, enhancing public visibility and credibility. Additionally, the company focuses on developing treatments for serious conditions such as peritumoral brain edema and severe migraine with aura through advanced clinical studies.

The strategic initiatives and transactions are expected to fortify Curatis Group’s market position, leveraging existing clinical data to expedite development processes and reduce overall investment risks.